tbuckley/cabot-search huggingface dataset:
TWO MEDICAL COLLEGE ASSOCIATIONS.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PTU-033 Serum metabolite profiles differentiate Crohn's disease from ulcerative colitis and from healthy controls
Authors: C Johnston, W Dunn, D Broadhurst, M Brown, A Makin, S Campbell, R Goodacre, W Newman, A J M Watson
Journal: Gut (2010)

<h3>Introduction</h3> Metabolomics is a powerful scientific strategy which identifies low molecular weight (bio)chemicals (metabolites) present in the metabolome of a cell, tissue or organism. The aim of this study was to undertake a two-stage metabolomic study of circulatory serum from patients with ulcerative colitis (UC) and Crohn9s disease (CD) and matched healthy controls, to determine if we could establish a characteristic metabolic signature for each of these diseases. <h3>Methods</h3> Patients were selected from a cohort of 332 IBD patients, comprising 134 males and 198 females during November 2007–March 2009. The base study comprised 30 CD, 30 UC and 29 control patients, all white male &lt;65 years old and of Caucasian ethnicity. The validation study comprised 31 CD, 28 UC and 29 matched control patients. In the validation study, multiple matched ethnicities were recruited. Serum was analysed by Ultra Performance Liquid Chromatography-Mass Spectrometry and subject to univariate analysis using Mann–Whitney or Student t test. <h3>Results</h3> After quality assurance, 4289 peaks were consistently detected by the UPLC-MS analysis of the base study samples. After univariate screening (p&lt;0.05) this was reduced to 909 information rich peaks which discriminated in pair-wise comparisons. Of these, 769 were also detected in the validation study (85%). For both data sets, there is good discrimination between each of the disease populations and the control populations. The degree of separation is similar for both diseases. The discrimination between UC and CD is less distinct;however there is a significant difference in the metabolic profiles, and therefore the phenotypes of the diseases. For each peak, in the base and validation data sets, three separate univariate comparisons were performed: CD vs. Control, UC vs. Control and, UC vs. CD. For CD vs. Control, 255 features had a p-value &lt; 0.05 in both the base and validation tests, compared with 138 significant features for UC vs control, and 35 significant features for UC vs. CD. Of these 117, 58 and 17, respectively were chemically identified and provided 61, 30 and 9 unique metabolite identification(s). <h3>Conclusion</h3> This study illustrates, for the first time, that serum metabolomics is effective at distinguishing IBD patients from normal subjects, and to a lesser extent CD from UC. It demonstrates the potential of metabolomics to differentiate disease phenotypes and may give new insights into the aetiology of IBD.
Premature Depolarization of Ventricular Cycle Suggested to Augment Cardiac Contraction
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Early magnesium modifications as a surrogate markers of efficacy of cetuximab-based anticancer treatment in KRAS wild-type colorectal cancer patients.
Authors: B. Vincenzi, D. Santini, S. Galluzzo, F. Loupakis, P. Correale, R. Addeo, S. Del Prete, A. Falcone, G. Francini, G. Tonini
Journal: Journal of Clinical Oncology (2010)

3564 Background: KRAS wild-type mutational status is necessary but not sufficient to get benefit from EGFR inhibition. Predictive markers are currently being evaluated including other EGFR downstream pathways and EGFR ligands. In the present study we reported hypomagnesemia as a predictor of efficacy and outcome in terms of TTP and OS in a selected cohort of patients affected by advanced colorectal adenocarcinoma KRAS wild-type cetuximab-treated. Methods: 143 patients affected by stage IV and histologically confirmed colorectal adenocarcinoma KRAS wild-type receiving cetuximab plus irinotecan as third-line anticancer treatment and resistant to oxaliplatin- and irinotecan-based chemotherapy were included. Magnesium plasma levels were measured before and 1, 7, 14 21, 28 days after cetuximab plus irinotecan infusion. Results: The median magnesium basal value showed a statistically significant decrease after the start of cetuximab plus irinotecan anticancer treatment (at 28 days, p < 0.0001). Patients with a decrease of magnesium levels > 50% compared to the basal level had a higher tumor response rate (55.8% vs. 16.7%, p < 0.0001), a longer TTP (6.3 vs. 3.6, p < 0.0001) and a longer median OS (11.0 vs. 8.1, p = 0.002) compared with those patients without magnesium modifications. Conclusions: We have shown that hypomagnesemia could be a predictor of efficacy and outcome in those patients harboring a wild type KRAS status treated with cetuximab plus irinotecan. There is growing evidence magnesium plays a key role in tumor biology. Criteria in selecting patients who are likely to benefit from cetuximab-based therapies are growing. Magnesium circulating level is an easy and economically inexpensive biomarker to routinely and serially be detected in patients cetuximab-treated. No significant financial relationships to disclose.
Passive Smoking among Schoolchildren in Israel
Authors: Ayana I. Goren, Sarah Hellman
Journal: Environmental Health Perspectives (1991)

A health survey was carried out among 8259 second- and fifth-grade schoolchildren living in three towns along the Israeli coast. The schoolchildren performed the following pulmonary function tests: forced vital capacity, forced expiratory volume in 1 sec, and peak expiratory flow, their parents filled out an American Thoracic Society-National Heart and Lung Institute health questionnaire. The aim of the survey was to study the impact of environmental and home exposures on the prevalence of respiratory conditions and on pulmonary function tests among Israeli schoolchildren. The health effects of exposure to passive smoking are discussed in detail. A trend of a higher frequency of reported respiratory conditions was found among schoolchildren whose fathers or mothers are smokers compared with children whose parents do not smoke. A statistically significant excess between 1.4% (for wheezing without cold) and 4.7% (for cough with cold) was found for children of smoking fathers; the excess for children of smoking mothers was between 1.6% (for wheezing with cold) and 3.6% (for cough with cold) compared with children of nonsmokers. A gradual excess in symptoms was found among children with none, one, and two smoking parents. Relative risks were found to be between 1.13 (for bronchitis) and 1.28 (for wheezing without cold) for children of smoking fathers, and between 1.24 (for asthma) and 1.41 (for cough with sputum) for children of smoking mothers, compared with 1.00 for children of nonsmokers. There was no consistent trend of reduced pulmonary function tests among children of smokers compared with nonsmokers' children.
Problems in Extrapolating Toxicity Data for Laboratory Animals to Man
Authors: R. L. Dixon
Journal: Environmental Health Perspectives (1976)

Some of the problems in extrapolating laboratory animal toxicity data to man are considered. The quantitative predictiveness of preclinical studies of anticancer drugs using dogs and monkeys for man has also been examined. The relationship between the maximum tolerated dose (MTD) in the dog, monkey, and the more sensitive of the two species and clinical observations are discussed. The effectiveness of using doses expressed on the basis of body weight (mg/kg) and body surface area (mg/m2) are compared. A method is introduced to assess the "statistical risk" associated with the extrapolation of the initial clinical (phase I) dose from experimental animal data. The best clinical prediction is obtained when one uses the experimental MTD expressed in mg/kg for the more sensitive of the large animal species (dogs or monkeys). The clinical introduction of a new anticancer agent at a dose 1/10 the MTD in the more sensitive species carries a statistical risk of about 3%; that is, the initial doses of about 3 of every 100 new drugs introduced into the clinic will produce some toxic effects in man. These same data have been extended theoretically to the total population and toxic chemicals in general. Reliable extrapolation from laboratory test models to man requires a much more complete understanding of structure--activity relationships, pharmacokinetic factors, and mechanisms of toxicity.
Can preliminary screening of dyspeptic patients allow more effective use of investigational techniques?
Authors: P M Davenport, A G Morgan, A Darnborough, F T De Dombal
Journal: BMJ (1985)

A total of 1041 patients with undiagnosed dyspepsia were interviewed to determine whether they required investigation for organic disease. The interviewer, a research assistant without medical qualifications, used a standard data sheet. The information obtained was analysed by computer, and, according to the results, patients were predicted to be at high, medium, or low risk. They were then followed up and the final diagnosis was compared with the risk predicted by computer. Patients predicted to be at low risk had a 10% chance of having ulcer disease and a 0.3% chance of having cancer, whereas patients predicted to be at high risk had a 20% chance of having ulcer disease and a 10% chance of having cancer. Appropriate preliminary screening of patients with acute dyspepsia can separate a group at low risk who will require investigation only if their symptoms do not resolve and a group at high risk requiring urgent outpatient consultation.
Notices
Authors: Jeanne Ryan
Journal: Hepatology (1997)

This post-graduate seminar for gastroenterologists, surgeons, radiologists, family practitioners and internists will focus on recent major advances in the diagnosis and treatment of gastrointestinal disease.Faculty members distinguished in the fields of surgery, gastroenterology, medicine and pathology will utilize a series of lectures, symposia and interactive case management sessions to present a variety of problematic topics.Additionally, ample opportunity will be available for informal discussion and close interaction between faculty and participants.Nineteen AMA Category 1 credits are available.
Chemically Induced Leukemia in Humans
Authors: Richard H. Adamson, Susan M. Seiber
Journal: Environmental Health Perspectives (1981)

The human population may be exposed to potentially leukemogenic agents, either in the form of drugs and food additives or as environmental contaminants and pollutants. However, in spite of the large number and diversity of these chemicals, only a few have been implicated as human leukemogens. One such agent is benzene, a known bone marrow depressant. A number of case reports have associated chronic exposure to this agent with the development of acute leukemia, as have several epidemiologic surveys. Treatment with various antitumor agents, including procarbazine, melphalan, thio-TEPA, chlorambucil, and cyclophosphamide, has also been associated with the development of acute leukemia. In addition, chloramphenicol and phenylbutazone have been implicated as human leukemogens, but the association between exposure to these two agents and acute leukemia appears at present to be weaker than it is for benzene and antitumor agent exposure. Despite such associations between exposure to chemicals and acute leukemia, several important problems exist with regard to implicating specific agents in the development of this neoplasm in man, including the paucity of animal models for chemically induced leukemia, and the frequent necessity to rely on single case reports or clusters of cases in which chemical exposures are associated with acute leukemia. Future efforts should be directed at performing properly designed and well executed epidemiologic studies, and at developing new in vitro and in vivo models for the study of this neoplasm.
CD11b Expression Is An Independent Adverse Prognostic Factor in Pediatric Acute Myeloid Leukemia Treated with Allogeneic Stem Cell Transplantation,
Authors: Maher Albitar, Amal Alseraihy, Mouhab Ayas, Abdullah Al-Jefri, Ali Al-Ahmari, Asim F Belgaumi, Claudia Ulrike Walter, Randa Nounou, Salem Khalil, Nasir Bakshi, Tarek Owaidah, Hassan El-Solh
Journal: Blood (2011)
A RESULT OF CLUB PRACTICE.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PP15. MICRORNA REGULATION OF INTRA-TUMOUR METABOLIC HETEROGENEITY IN GLIOBLASTOMA MULTIFORME
Authors: Ms Huda Alfardus, Dr Maria de los Angeles Estevez-Cebrero, Dr Anbarasu Lourdusamy, Prof Richard Grundy, Dr Alan Mcintyre, Dr Stuart Smith
Journal: Neuro-Oncology (2017)
RETROPERITONEAL PELVIC ABSCESSES
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Practical Medicine Series, Comprising Ten Volumes on the Year's Progress in Medicine and Surgery.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HIV-infected professionals, patient rights, and the 'switching dilemma'
Authors: N. Daniels
Journal: JAMA (1992)

The ethical issues surrounding the Centers for Disease Control and American Medical Association guidelines for health professionals infected with the human immunodeficiency virus are examined and discussed. Although human immunodeficiency virus transmission risks during surgery are lower than many risks we routinely face, it is not irrational for a patient to want to switch from an infected professional to an uninfected one. The American Medical Association claim that physicians have a duty to avoid imposing any identifiable risks is implausible. Knowing the Centers for Disease Control estimate of risks gives us no way to decide whether the rights of patients or those of handicapped (infected) workers should be given priority. Granting priority to patient rights, either by giving patients the opportunity to know the risks they face and to switch to another provider, or by removing infected providers (compulsory switching), makes us all worse off. This gives us reason to reject these guidelines and emphasize other infection control measures. (<i>JAMA</i>. 1992;267:1368-1371)
CANCER RESEARCH
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
^131I Dosage
Authors: NORMAN G. SCHNEEBERG
Journal: Annals of Internal Medicine (1978)

Letters and Corrections1 April 1978131I DosageNORMAN G. SCHNEEBERG, M.D.NORMAN G. SCHNEEBERG, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-88-4-580_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: The ubiquity of postradiation hypothyroidism after treatment of Graves' disease with 131I has fostered various attempts to thwart this complication. The most fashionable approach today is to substantially reduce the dose of 131I. The result has been a lower incidence of hypothyroidism. For example, Smith and Wilson (1) lowered the conventional dose of 7000 rad to 3500 rad and reduced hypothyroidism from 29% to 5% in the first 5 years of follow-up. The smaller dose, however, frequently delays cure of hyperthyroidism and necessitates the use of an antithyroid drug or propanolol during the toxic interval.Roudebush, Hoye...References1. SMITHWILSON RG: Clinical trial of different doses of 131I in treatment of thyrotoxicosis. Br Med 11:129-132, 1967 CrossrefGoogle Scholar2. ROUDEBUSHHOYEDEGROOT CKL: Compensated low-dose 131I therapy of Graves' disease. Ann Intern Med 87:441-443, 1977 LinkGoogle Scholar3. FREEDBERG A: Iodine-131 in the treatment of hyperthyroidism. Studies of dosage and metabolism, in Radio Isotopes in Medicine, edited by ANDREWS GA, BRUCER M, ANDERSON EB. Washington, D.C., U.S. Atomic Energy Commission, 1953, p. 298 Google Scholar4. QUIMBY E: Physical aspects of radioiodine use, in The Thyroid Gland, 2nd ed., edited by WERNER SC. New York, Paul B. Hoeber, Inc., 1962, p. 181 Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: 191 Presidential Blvd.; Bala Cynwyd, PA 19004 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1978Volume 88, Issue 4Page: 580-580KeywordsDrugsHyperthyroidismHypothyroidism Issue Published: 1 April 1978 PDF DownloadLoading ...